• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Innovations in Cardiovascular Disease Management: Latest Surgical Procedures, Drugs and Medical Devices

Posted on: Monday, 17 September 2007, 06:00 CDT

Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is now available to its catalogue.

Innovations in Cardiovascular Disease Management: Latest surgical procedures, drugs and medical devices

http://www.reportlinker.com/p058864/Cardiovascular-Disease- Management.html

(Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting growth in prevalence, where the insurgence of CVD has exacerbated the risk factors associated with indigenous communicable diseases. Keeping pace with epidemiological change in both the developed and developing world constitutes the overriding challenge for industrial players, and involves successfully integrating into localised healthcare systems and reimbursement structures, in addition to remaining aligned with product demand. In the medical device, pharmaceutical and biotechnology industries, this challenge is being met with a focus on products that reduce adverse effects, improve patient outcomes and extend the range of formulations for existing indications. 'Innovations in Cardiovascular Disease Management' is a new report that will examine the major developments shaping the future of the cardiovascular industry. This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market. The extent to which these products can stimulate the growth and development of the future market will also be assessed. Use this report to evaluate the potential of new and emerging products in the treatment of cardiovascular diseases, assess the strength of competitor pipelines and identify future market opportunities...

Table of content

Executive Summary

The Management of Cardiovascular Disease

Cardiovascular and Interventional Procedures

Emerging Coronary Stents and Stent Systems

Innovations in Minimally Invasive Cardiac Surgery

Cardiovascular Drugs in Early Stage Development

New and Emerging Cardiovascular Drugs

Chapter 1 The Management of Cardiovascular Disease

Summary

Introduction

The Global Burden of Cardiovascular Disease

CVD remains the leading cause of death in the United States

CVD Rates in Central and Eastern Europe

Noncommunicable Diseases in the Developing World

Background to the Major Cardiovascular Conditions

Coronary Artery Disease (CAD)

Atherosclerosis

Angina Pectoris

Acute Myocardial Infarction (MI)

Heart Valve Disorders

Aortic heart valve

Mitral Valve Disease

Pulmonary Valve Disease

Tricuspid Valve Disease

High Blood Pressure: Hypertension

Heart Rhythm Disorders (Heart Arrhythmia)

Peripheral Vascular Disease

Peripheral Artery Disease (PAD)

Peripheral Venous Disorders (PVD)

Stroke or Cerebrovascular Accidents (CVA)

Ischaemic Stroke

Haemorrhagic stroke

Chapter 2 Latest Developments in Cardiovascular and PCI Procedures

Summary

Introduction to Percutaneous Coronary Interventions

Indications for PCI

PCI Procedural Volumes

PCI Used Primarily to Treat Unstable Angina and acute ST-elevation MI

Inter-country Variance in PCI Procedural Rates

China and India: Huge growth potential and market development

Latest Developments in PCI Procedures

Embolic Protection Devices

Current Products

Development Stage Products and Current Status

Future Technologies and Trends

Coronary Atherectomy

Rotational Coronary Atherectomy (Rotoblation)

Directional Coronary Atherectomy (DCA)

Orbital Atherectomy

Ablative laser-assisted angioplasty

Chapter 3 Emerging Coronary Stents and Stent Systems

Summary

Emerging Coronary Stents and Stent Systems

Key Events

Introduction of Drug-Eluting Stents (DES)

Development of Drug-Eluting Stents

Sirolimus (Rapamycin)

Paclitaxel

Tacrolimus

Everolimus (RAD-001)

Zotarolimus (also called ABT-578)

DES -- Recent News, Product Developments and Clinical Trial Updates

Market Developments and Forecasts for Drug-Eluting Stents

Emergence of Bioabsorbable Stents

Biomaterials and Bioabsorbable Polymers

Further Coronary Stent Developments and Technological Trends

Novel Coating Technologies

Gene Therapy technologies and its Potential Use to Prevent Restenosis

Coronary Stents and Endothelial Progenitor Cells (EPCs)

Nanotechnologies and Drug-Eluting Coronary Stents

Development of Novel Estradiol Containing Drug-Eluting Stents

Stem-Cell Derived Endovascular Cells

Chapter 4 Innovations in Minimally Invasive Cardiac Surgery (MICS)

Summary

Introduction

Minimally Invasive Direct Coronary Artery Bypass (MID-CAB)

Indications for MIDCAB

Off-Pump Coronary Artery Bypass (OP-CAB)

Indications for OP-CAB

Minimally Invasive Port Access

Indications for Minimally Invasive Port Access

Robotic Assisted Coronary Artery Bypass (RA-CAB)

Current and Emerging Technologies

Robotics in Minimally Invasive Cardiac Surgery

Robotic Systems

Computer Aided Cardiac Surgery

Virtual Reality in Cardiac Surgery

Laser Heart Surgery or transmyocardial Laser revascularization (TMLR)

The CO2 Heart Laser System

The holmium:YAG (yttrium aluminium garnet) laser

The excimer laser

Chapter 5 Cardiovascular Drugs in Early Stage Development

Summary

Introduction

Early Developments in Key Cardiovascular Disease Classes

Angina

Arrhythmiasis

Atherosclerosis

Atrial Fibrillation

Congestive Heart Failure

Hypercholesterolemia

Hypertension

Myocardial Infarction

Thrombosis

Chapter 6 New and Emerging Cardiovascular Drugs

Summary

Introduction

Anti-Hypertensives

Tekturna (Aliskiren)

Development of a New Class of Renin Inhibitors

Exforge (valsartan plus amlodipine)

CHF-1521

Cleviprex(TM) (Clevidipine)

Antihypertensives: Current Pipeline and Late Stage Development

Cardoxal (MC-4232) (MC-1 cardioprotectant plus lisinopril)

Darusentan

Ambrisentan

Nebivolol

Zanipress® / Zanitek®

Thelin™ (Sitaxsentan)

TBC3711

Anti-Dyslipidemics

Pfizer discontinues torcetrapib development

R1658

Simcor (Niaspan® (extended-release niacin) and simvastatin (generic Zocor®))

CRESTOR® (rosuvastatin) and CRESTOR/ABT-335 combination

Synordia

Lapaquistat (TAK-475)

SLx-4090

AEGR-733

Compound Number 256073 and 501516

LBM642

Dyslipidaemia: Current Pipeline and Late Stage Development

Anti-Thrombotics

Rivaroxaban (BAY59-7939)

Rendix (dabigatran etexilate, BIBR-1048)

Idraparinux

Apixaban

SSR-126517

Exanta/ximelagatran

Anti-Thrombotics: Current Pipeline and Late Stage Development

Anti-Arrhythmics

Stedicor (Azimilide)

Multaq (Dronedarone)

Vernakalalant (RSD 1235)

Tecadenoson CVT510

Pulzium IV (Tedisamil)

Anti-Arrhythmics: Current Pipeline and Late Stage Development

Chapter 7 Appendix

Methodology Statement

Primary Data and Information Gathering

Secondary Data and Information Gathering

Market Share Analysis and Market Forecast Predictions

Glossary

Index

List of Figures

Figure 1.1: Breakdown of Deaths from Cardiovascular Diseases, USA 2002

Figure 1.2: Leading causes of death in developing countries, 2002

Figure 2.3: Use of Percutaneous Coronary Intervention in Europe, 2005

Figure 3.4: Estimated number of Stent Procedures (BMS & DES) % Total Number of PTCA

Procedures

Figure 3.5: Actual and projected revenues from Coronary Stents, Worldwide sales- 2006

Figure 3.6: Market Share Analysis, DES v BMS World, 2006

List of Tables

Table 1.1: Age- and gender-specific incidence of recognised MI

Table 1.2: Age- and gender-specific incidence of unrecognised MI

Table 2.3: Estimated volume of cardiovascular procedures by region (US 2002)

Table 2.4: PCI procedure rates in Selected Countries, 2005

Table 5.5: Selected Early Stage Anti Anginal Drug Developments

Table 5.6: Selected Early Stage Anti Arrhythmiasis Drug Developments

Table 5.7: Selected Early Stage Atherosclerosis Drug Developments

Table 5.8: Selected Early Stage Atrial Fibrillation Drug Developments

Table 5.9: Selected Early Stage Congestive Heart Failure Drug Developments

Table 5.10: Selected Early Stage Hypercholesterolemia Drug Developments

Table 5.11: Selected Early Stage Hypertension Drug Developments

Table 5.12: Selected Early Stage Myocardial Infarction Drug Developments

Table 5.13: Selected Early Stage Thrombosis Drug Developments

Table 6.14: Characteristics of Major Classes of Lipoproteins

Table 6.15: AstraZeneca's Current Anti-Dyslipidaemia Pipeline

Table 6.16: Classification of Anti-Arrhythmics

More market research reports? Go to http://www.reportlinker.com

http://www.reportlinker.com/ci0228/Cardiovascular-diseases-market -research.html

http://www.reportlinker.com/ci0133/Pharmaceutical-industry-market -research.html http://agribusinessmarket.wordpress.com

(Due to their length, these URLs may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.)

Source: Business Wire

More News in this Category